Pangali EV/EBITDA: NewAmsterdam Pharma N.V. (NAMS)

NewAmsterdam Pharma relies on external contractors for production and testing to maintain workforce flexibility. This EV/EBITDA multiple chart on GURU.Markets reflects the market valuation, where 0.00 represents the current metric. However, geopolitics are limiting capital inflows into risk assets, and the company's success is critically dependent on the final stages of development for its cardiometabolic drugs.

This metric measures the total enterprise value relative to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets accounting for the debt load. For NewAmsterdam Pharma (NAMS), which delegates testing to external contractors, the EV/EBITDA ratio including depreciation and debt is critical, as it reflects the efficiency of a lean patent management structure against high outsourcing costs.